$558.01
5.16% today
Nasdaq, Jan 06, 10:00 pm CET
Why the stock moved Why the stock moved Beta
ISIN
US5588681057
Symbol
MDGL

Madrigal Pharmaceuticals, Inc. Stock price

$588.40
+11.10 1.92% 1M
+299.23 103.48% 6M
+6.06 1.04% YTD
+267.59 83.41% 1Y
+316.69 116.55% 3Y
+479.86 442.10% 5Y
+576.53 4,857.66% 10Y
+270.25 84.94% 20Y
Nasdaq, Closing price Mon, Jan 05 2026
-5.47 0.92%
ISIN
US5588681057
Symbol
MDGL
Industry

New AI Insights on Madrigal Pharmaceuticals, Inc. Insights AI Insights on Madrigal Pharmaceuticals, Inc.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$13.4b
Enterprise Value
$12.6b
Net debt
positive
Cash
$1.1b
Shares outstanding
22.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
18.0 | 13.9
EV/Sales
17.0 | 13.1
EV/FCF
negative
P/B
21.4
Financial Health
Equity Ratio
72.4%
Return on Equity
-61.8%
ROCE
-31.7%
ROIC
-
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$740.6m | $964.9m
EBITDA
$-306.0m | $-293.9m
EBIT
$-307.5m | $-298.2m
Net Income
$-289.1m | $-244.2m
Free Cash Flow
$-164.6m
Growth (TTM | estimate)
Revenue
864.3% | 435.6%
EBITDA
44.1% | 40.9%
EBIT
43.9% | 40.1%
Net Income
44.3% | 47.6%
Free Cash Flow
62.4%
Margin (TTM | estimate)
Gross
95.3%
EBITDA
-41.3% | -30.5%
EBIT
-41.5%
Net
-39.0% | -25.3%
Free Cash Flow
-22.2%
More
EPS
$-12.9
FCF per Share
$-7.3
Short interest
18.9%
Employees
528
Rev per Employee
$340.0k
Show more

Is Madrigal Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,084 stocks worldwide.

Madrigal Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast:

21x Buy
91%
2x Hold
9%

Analyst Opinions

23 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast:

Buy
91%
Hold
9%

Financial data from Madrigal Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
741 741
864% 864%
100%
- Direct Costs 35 35
1,160% 1,160%
5%
706 706
853% 853%
95%
- Selling and Administrative Expenses 715 715
110% 110%
97%
- Research and Development Expense 298 298
6% 6%
40%
-306 -306
44% 44%
-41%
- Depreciation and Amortization 1.48 1.48
70% 70%
0%
EBIT (Operating Income) EBIT -307 -307
44% 44%
-42%
Net Profit -289 -289
44% 44%
-39%

In millions USD.

Don't miss a Thing! We will send you all news about Madrigal Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Madrigal Pharmaceuticals, Inc. Stock News

Positive
The Motley Fool
one day ago
Nektar Therapeutics has a promising lead drug candidate, but there is considerable risk involved. Madrigal Pharmaceuticals is generating strong revenue from a medicine with significant prospects.
Positive
Seeking Alpha
one day ago
Madrigal Pharmaceuticals maintains a "Strong Buy" rating, driven by Rezdiffra's FDA approval for F2-F3 MASH and robust sales momentum. MDGL is expanding Rezdiffra's reach, targeting F4 compensated MASH cirrhosis with the pivotal phase 3 MAESTRO-NASH-OUTCOMES trial; data is expected in 2027. Two-year open-label data show Rezdiffra improves key biomarkers in hard-to-treat F4c MASH cirrhosis patie...
Neutral
GlobeNewsWire
19 days ago
CONSHOHOCKEN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on December 15, 2025 to 4 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Induc...
More Madrigal Pharmaceuticals, Inc. News

Company Profile

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Head office United States
CEO William Sibold
Employees 528
Founded 2011
Website www.madrigalpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today